Grant Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 13, 2022	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities		$ 83,012	$ 98,521
Other long-term liabilities		21,578	14,577
Restricted cash and cash equivalents, current		1,922	89,385	$ 13,268
Vaccinal Antibody Grant | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants		2,000	4,600	13,300
BARDA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant awarded amount. maximum					$ 50,100	$ 55,000
BARDA | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant awarded amount. maximum					$ 11,200
Gates Foundation | Vaccinal Antibody Grant
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unused grant funds returned		9,500
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Unrecognized premiums		9,300
Accrued and other liabilities		1,800	11,600
Deferred revenue		0	11,100
Restricted cash and cash equivalents, current		1,800
Gates Foundation | Vaccinal Antibody Grant | Accrued Liabilities and Other Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premiums		1,900
Gates Foundation | Vaccinal Antibody Grant | Other Noncurrent Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premiums		$ 7,400
BARDA | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			$ 5,900	$ 33,400